- Continuing to lead the technological transformation of single-use endoscopy

Zsquare, a leading developer of high-performance, single-use endoscopes, has 
raised $15M in financing for the soft launch of its disruptive single-use ENT 
endoscope and further R&D to expand potential use in other indications. The 
soft launch is planned following FDA clearance expected in the third quarter of 
2022.

This $15M round of financing was led by Chartered Group, a private equity firm 
specializing in disruptive technologies with a far-reaching presence in Europe 
and Asia. This is their second consecutive investment in Zsquare, signaling 
strong confidence in the company’s technology and growth potential. 

“We are excited to witness and support the maturation of Zsquare’s disruptive 
technology and are confident that it will bring significant benefits to the 
world of endoscopy by changing the entire cost-benefit structure of these 
widely used devices”, says Eyal Agmoni, Chairman of Chartered Group.

Zsquare's high-performance, single-use endoscopic platform 
[https://www.zsquaremedical.com/] is designed to improve diagnostic 
performance, eliminate risk of cross-infection and dramatically reduce 
healthcare costs. With a hybrid design that includes a universal, reusable 
imaging core and alternating, indication-specific disposable shells it is 
capable of addressing multiple indications, as well as solving unmet imaging 
needs for new indications. 

According to Asaf Shahmoon, CEO and co-founder of Zsquare, “As the world is 
rapidly moving towards single-use devices, Zsquare is advancing to introduce 
new groundbreaking technologies and capabilities to this up-and-coming market. 
This round will help the company advance our go-to-market plan for the initial 
ENT product, as well as ramp up R&D for next generation capabilities and 
further indications.”

Zsquare’s unique design [https://www.zsquaremedical.com/#Products] overcomes 
the inherent diameter versus image quality tradeoff of conventional 
chip-on-the-tip designs, in a cost-effective way. Zsquare's solution houses the 
less costly optics in a single-use shell, with high-value imaging electronics 
in a detachable, reusable imaging core. The result is a cost-effective solution 
that dramatically reduces the optical component's diameter without compromising 
on image resolution, eliminates the risk of cross-contamination, and enables 
access to anatomies that could never be properly imaged before.

“Zsquare’s single-use endoscopic platform is showcasing remarkable, never-seen 
before high-resolution images, using a flexible scope with an imaging diameter 
of less than 0.5mm” says Prof. Hisao Tajiri, M.D., Senior Advisor of the Japan 
Gastroenterological Endoscopy Society (JGES) and member of Zsquare Scientific 
Advisory Board. “This groundbreaking innovation will usher in a new era in 
endoscopy, combining superior diagnostic capabilities with an excellent safety 
profile.”

About Zsquare:

Zsquare, a privately held medical device company with headquarters in Israel, 
develops cost-effective, high-performance, single-use endoscopes to enable 
access to unserved indications, improve performance in current practices, and 
solve the industry's cross-contamination problem.

Logo - https://mma.prnewswire.com/media/1136770/Zsquare_Logo.jpg


Media Contact: 
Chen Goldstein
+972-524258183
chen.goldstein@zsquaremedical.com

Source: Zsquare